New Aspects of Tyrosine Kinase Inhibitors


Related Videos (117)

In this second video on refractory thyroid cancer, Marcia Brose, MD, reviews recent findings from clinical practice and evolving clinical trials in the context of tyrosine kinase inhibitor therapy for refractory thyroid cancer. Among the subjects Dr. Brose considers are the addition of the mTOR inhibitor everolimus to therapy for patients whose disease is progressing on sorafenib, vemurafenib in patients with BRAF V600E-­positive progressive papillary thyroid cancer and the Phase 1 trial of cabozantinib.


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®